OTHERS_CITABLE
Precision Medicine in Non Communicable Diseases
Non-communicable diseases (NCDs) are the leading cause of death and disease burden globally, cardiovascular diseases account for the major part of death related to NCDs followed by different types of cancer, chronic obstructive pulmonary disease, and diabetes. As the world health organization and the United Nations have announced a 25% reduction in mortality of NCDs by 2025, different communities need to adopt preventive strategies for achieving this goal. Personalized medicine approach as a predictive and preventive strategy aims for a better therapeutic goal to the patients in order to maximize benefits and reduce harms. The clinical benefits of this approach are already realized in cancer targeted therapy, and its impact on other conditions needs more studies in different societies. In this review, we essentially describe the concept of personalized (or precision) medicine in association with NCDs and the future of precision medicine in prediction, prevention, and personalized treatment.
http://ijmcmed.org/article-1-1039-en.pdf
2019-08-28
1
18
10.22088/IJMCM.BUMS.8.2.1
Precision medicine
non-communicable diseases
cardiovascular diseases
type 2 diabetes
chronic obstructive pulmonary disease
cancer
Mandana
Hasanzad
mandanahasanzad@yahoo.com
1
Medical Genomics Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; Personalized Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
https://orcid.org/0000-0002-0538-1135
Negar
Sarhangi
nsarhangi198@gmail.com
2
Personalized Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
https://orcid.org/0000-0003-2385-7333
Hamid Reza
Aghaei Meybodi
dr_aghai@yahoo.com
3
Personalized Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
https://orcid.org/0000-0003-1754-3450
Shekoufeh
Nikfar
shekoufeh.nikfar@gmail.com
4
Personalized Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran; Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
https://orcid.org/0000-0002-5206-6197
Fatemeh
Khatami
fatemehkhatami1978@gmail.com
5
Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
https://orcid.org/0000-0002-6311-1336
Bagher
Larijani
larijanib1340@gmail.com
6
Personalized Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran; Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
https://orcid.org/0000-0001-5386-7597
OTHERS_CITABLE
Liquid Biopsy as a Minimally Invasive Source of Thyroid Cancer Genetic and Epigenetic Alterations
In the blood of cancer patients, some nucleic acid fragments and tumor cells can be found that make it possible to trace tumor changes through a simple blood test called “liquid biopsy”. The main components of liquid biopsy are fragments of DNA and RNA shed by tumors into the bloodstream and circulate freely( ctDNAs and ctRNAs). tumor cells which are shed into the blood (circulating tumor cells or CTCs), and exosomes that have been investigated for non-invasive detection and monitoring of several tumors including thyroid cancer. Genetic and epigenetic alterations of a thyroid tumor can be a driver for tumor genesis or essential for tumor progression and invasion. Liquid biopsy can be real-time representative of such genetic and epigenetic alterations in order to trace tumors. In thyroid tumors, the circulating BRAF mutation is now taken into account for both thyroid cancer diagnosis and determination of the most effective treatment strategy. Several recent studies indicate the ctDNA methylation pattern of some iodine transporters and DNA methyltransferase as a diagnostic and prognostic biomarker in thyroid cancer as well. There is a big hope that the recent advances of genome sequencing together with liquid biopsy can be a game changer in oncology.
http://ijmcmed.org/article-1-1038-en.pdf
2019-07-05
19
29
10.22088/IJMCM.BUMS.8.2.19
Liquid biopsy
ctDNA
circulating tumor cells
exosomes
mutation
methylation
Fatemeh
Khatami
fatemehkhatami1978@gmail.com
1
Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
Bagher
Larijani
larijanib@tums.ac.ir
2
Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
Shirzad
Nasiri
nasiri@tums.ac.ir
3
Departments of Surgery, Tehran University of Medical Sciences, Shariati Hospital, Tehran, Iran.
AUTHOR
Seyed Mohammad
Tavangar
tavangar@ams.ac.ir
4
Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran; Departments of Pathology, Dr. Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
OTHERS_CITABLE
Metabolomics Analysis of Mesenchymal Stem Cells
Various mesenchymal stem cells as easily accessible and multipotent cells can share different essential signaling pathways related to their stemness ability. Understanding the mechanism of stemness ability can be useful for controlling the stem cells for regenerative medicine targets. In this context, OMICs studies can analyze the mechanism of different stem cells properties or stemness ability via a broad range of current high-throughput techniques. This field is fundamentally directed toward the analysis of whole genome (genomics), mRNAs (transcriptomics), proteins (proteomics) and metabolites (metabolomics) in biological samples. According to several studies, metabolomics is more effective than other OMICs ّfor various systems biology concerns. Metabolomics can elucidate the biological mechanisms of various mesenchymal stem cells function by measuring their metabolites such as their secretome components. Analyzing the metabolic alteration of mesenchymal stem cells can be useful to promote their regenerative medicine application.
http://ijmcmed.org/article-1-1044-en.pdf
2019-07-05
30
40
10.22088/IJMCM.BUMS.8.2.30
Mesenchymal stem cells
metabolic pathways
metabolomics
systems biology
Parisa
Goodarzi
pr_goodarzi@yahoo.com
1
Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
Sepideh
Alavi-Moghadam
sepidalavi@gmail.com
2
Cell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
Moloud
Payab
moloud.payab@gmail.com
3
Obesity and Eating Habits Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
Bagher
Larijani
larijanib1340@gmail.com
4
Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical sciences, Tehran, Iran.
AUTHOR
Fakher
Rahim
bioinfo2003@gmail.com
5
Health Research Institute, Thalassemia and Hemoglobinopathies Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
AUTHOR
Kambiz
Gilany
k.gilany@ari.ir
6
Integrative Oncology Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran; Department of Biomedical Sciences, University of Antwerp, Belgium.
AUTHOR
Nikoo
Bana
Niko_bana@yahoo.com
7
Metabolomics and Genomics Research Center, Endocrinology and Metabolism Molecular- Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
Akram
Tayanloo-Beik
A.tayanloo@gmail.com
8
Cell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
Najmeh
Foroughi Heravani
najmeh_foroughi@yahoo.com
9
Cell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
Mahdieh
Hadavandkhani
mahdiehhadavandkhani1376@yahoo.com
10
Cell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
Babak
Arjmand
barjmand@sina.tums.ac.ir
11
Cell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. Metabolomics and Genomics Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
https://orcid.org/0000-0001-5001-5006
OTHERS_CITABLE
Metabolomics and Cell Therapy in Diabetes Mellitus
Diabetes with a broad spectrum of complications has become a global epidemic metabolic disorder. Till now, several pharmaceutical and non-pharmaceutical therapeutic approaches were applied for its treatment. Cell-based therapies have become promising methods for diabetes treatment. Better understanding of diabetes pathogenesis and identification of its specific biomarkers along with evaluation of different treatments efficacy, can be possible by clarification of specific metabolic modifications during the diabetes progression. Subsequently, metabolomics technology can support this goal as an effective tool. The present review tried to show how metabolomics quantifications can be useful for diabetic monitoring before and after cell therapy. Cell therapy is an alternative approach to achieve diabetes treatments goals including insulin resistance amelioration, insulin independence reparation, and control of glycemia. OMICs approaches provide a comprehensive insight into the molecular mechanisms of cells features and functional mechanism of their genomics, transcriptomics, proteomics, and metabolomics profile which can be useful for their therapeutic application. As a modern technology for the detection and analysis of metabolites in biological samples, metabolomica can identify many of the metabolic and molecular pathways associated with diabetes and its following complications.
http://ijmcmed.org/article-1-1040-en.pdf
2019-05-20
41
48
10.22088/IJMCM.BUMS.8.2.41
Cell Therapy
Diabetes Mellitus
Metabolic Diseases
Metabolomics
Metabolic Pathways
Bagher
Larijani
larijanib1340@gmail.com
1
Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical sciences, Tehran, Iran
AUTHOR
https://orcid.org/0000-0001-5386-7597
Parisa
Goodarzi
pr_goodarzi@yahoo.com
2
Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Moloud
Payab
payab@gmail.com
3
Obesity and Eating Habits Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Sepideh
Alavi-Moghadam
sepidalavi@gmail.com
4
Cell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Fakher
Rahim
bioinfo2003@gmail.com
5
Health Research Institute, Thalassemia and Hemoglobinopathies Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
AUTHOR
Nikoo
Bana
Niko_bana@yahoo.com
6
Metabolomics and Genomics Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Mina
Abedi
min.a1220@yahoo.com
7
Cell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Maryam
Arabi
Maryam.arabi98@gmail.com
8
Cell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Hossein
Adibi
adibihastam@gmail.com
9
Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Kambiz
Gilany
k.gilany@ari.ir
10
Department of Biomedical Sciences, University of Antwerp, Belgium; Integrative Oncology Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran
AUTHOR
https://orcid.org/0000-0003-2916-7245
Babak
Arjmand
barjmand@sina.tums.ac.ir
11
Cell Therapy and Regenerative Medicine Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. Metabolomics and Genomics Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
https://orcid.org/0000-0001-5001-5006
ORIGINAL_ARTICLE
The Role of ERRFI1+808T/G Polymorphism in Diabetic Nephropathy
Nephropathy is a common diabetes complication. ERRFI1 gene which participates in various cellular pathways has been proposed as a candidate gene in diabetic nephropathy. This study aimed to investigate the role of +808T/G polymorphism (rs377349) in ERRFI1 gene in diabetic nephropathy. In this case-control study, patients including diabetes with nephropathy (DN=104), type 2 diabetes without nephropathy (DM=100), and healthy controls (HC=106) were included. DNA was extracted from blood, and genotyping of the +808T/G polymorphism was carried out using PCR-RFLP technique. The differences for genotype and allele frequencies for +808T/G polymorphism in ERRFI1 gene between DN vs. HC and DN+DM vs. HC were significant (P<0.05) while no significant difference between DN and DM was observed. The allele frequencies were significantly different in DN vs. HC and DN+DM vs. HC in males but not in females. G allele of +808T/G polymorphism in ERRFI1 gene has no significant role in development and progression of diabetic nephropathy in diabetes patients while it is a risk allele for developing diabetes in Iranian population.
http://ijmcmed.org/article-1-1043-en.pdf
2019-07-05
49
55
10.22088/IJMCM.BUMS.8.2.49
ERRFI1
+808T/G
polymorphism
rs397349
diabetic nephropathy
Saeedeh
Asgarbeik
SSAsgarbeik@yahoo.com
1
Department of Cellular and Molecular Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran.
AUTHOR
Mahsa
Mohammad Amoli
mmamoli@hotmail.com
2
Metabolic Disorders Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
Samaneh
Enayati
sEnayati@yhoo.com
3
Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
Fatemeh
Bandarian
fbandarian@tums.ac.ir
4
Personalized Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
Ensieh
Nasli-Esfahani
n.nasli@yahoo.com
5
Obesity and Eating Habits Research Center, Endocrinology and Metabolism Molecular -Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
Katayoon
Forouzanfar
Katayoonforouzanfar@yahoo.com
6
Elderly Health Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
Farideh
Razi
swt_f@yahoo.com
7
Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
Seyed Abdolhamid
Angaji
SA_angaji@yahoo.com
8
Department of Cellular and Molecular Biology, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran.
AUTHOR
ORIGINAL_ARTICLE
Association Analysis of the Common Genetic Variants of HNF4A Gene with Type 2 Diabetes Mellitus Risk
Type 2 diabetes mellitus (T2DM) is a complex disease that involves a wide range of genetic and environmental factors. The hepatocyte nuclear factor (HNF4A) carries out hepatic gluconeogenesis regulation and insulin secretion crucially, and the corresponding gene was shown to be linked to T2DM in several studies. The aim of the present study was to evaluate the association between HNF4A genetic variants (rs1884613 and rs1884614) and T2DM risk in a group of Iranian patients. This case-control study included 100 patients with T2DM and 100 control subjects. Genotyping of two single nucleotide polymorphisms (SNPs) (rs1884613 and rs1884614) of HNF4A was performed using the sequencing method. There was no statistically significant difference for allele and genotype distribution of the HNF4A common variants (rs1884613 and rs1884614) between subjects with and without T2DM (P=0.9 and P=0.9, respectively). Regarding diabetic complications, although the presence of mentioned polymorphisms increased the odds of developing ophthalmic complications and reduction of the odds of renal complications among diabetic patients, the mentioned risk was non- significant and cannot be generalized to the whole population. It seems that rs1884613 and rs1884614 polymorphisms are not associated with T2DM or its renal and ophthalmic complications. To investigate the precise influence of these polymorphisms, prospective cohorts with larger sample sizes are required.
http://ijmcmed.org/article-1-1041-en.pdf
2019-12-04
56
62
10.22088/IJMCM.BUMS.8.2.56
T2DM
T2DM complication
HNF4A
Gene
Sequencing
Seyedeh Mina
Azizi
mina.azii2012@gmail.com
1
Medical Genomics Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
AUTHOR
Negar
Sarhangi
nsarhangi198@gmail.com
2
Personalized Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran, Iran.
AUTHOR
https://orcid.org/0000-0003-2385-7333
Mahdi
Afshari
mahdiafshari99@gmail.com
3
Department of Community Medicine, Zabol University of Medical Sciences, Zabol, Iran.
AUTHOR
https://orcid.org/0000-0002-5452-514X
Davood
Abbasi
drdavoodabbasi@yahoo.com
4
Iranian Diabetes Society, Eslamshahr Branch, Iran.
AUTHOR
Hamid Reza
Aghaei Meybodi
dr_aghai@yahoo.com
5
Personalized Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran, Iran.
AUTHOR
https://orcid.org/0000-0003-1754-3450
Mandana
Hasanzad
mandanahasanzad@yahoo.com
6
Medical Genomics Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; Personalized Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran, Iran.
AUTHOR
https://orcid.org/0000-0002-0538-1135
ORIGINAL_ARTICLE
The Association Analysis of Vascular Endothelial Growth Factor -2549 Insertion/Deletion Variant and Endometriosis Risk
Endometriosis is a debilitating disorder, defined as the presence of endometrial gland and stroma outside of the uterus. It may affect angiogenesis and vascular endothelial growth factor (VEGF) is one of the angiogenic factors that plays an important role in both physiological and pathological angiogenesis. The present study aimed to evaluate the association of VEGF -2549 insertion/deletion (I/D) polymorphism with endometriosis. This case-control study enrolled 244 (100 cases and 144 controls) women who were admitted for laparoscopy or laparotomy for gynecological procedures. Genomic DNA was separated from peripheral blood leukocytes and polymerase chain reaction amplification was performed for genotyping of the VEGF gene Insertion/Deletion (I/D) polymorphism. The frequency of the II, ID, and DD genotype was 14%, 52% and 34% in patients versus 18.8%, 47.8% and 34% in controls. The results did not provide any evidence supporting the endometriosis risk related to the VEGF polymorphism in Iranian women population.
http://ijmcmed.org/article-1-1045-en.pdf
2019-07-05
63
68
10.22088/IJMCM.BUMS.8.2.63
Endometriosis
vascular endothelial growth factor
VEGF
-2549 I/D
polymorphism
Negar
Sarhangi
nsarhangi198@gmail.com
1
Personalized Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran; Metabolic Disorders Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
https://orcid.org/0000-0003-2385-7333
Shahrzad
Mohseni
shmohseni58@gmail.com
2
Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
https://orcid.org/0000-0003-3641-0805
Soheila
Aminimoghaddam
aminimoghaddam.s@iums.ac.ir
3
Department of Obstetrics and Gynecology, Iran University of Medical Sciences, Tehran, Iran.
AUTHOR
https://orcid.org/0000-0001-6988-5722
Batool
Hossein Rashidi
bhrashidi@gmail.com
4
Vali-e-Asr Reproductive Health Research Center, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
https://orcid.org/0000-0002-4897-0087
Fedyeh
Haghollahi
fedyeh_hagh@yahoo.com
5
Department of Obstetrics and Gynecology, Iran University of Medical Sciences, Tehran, Iran.
AUTHOR
https://orcid.org/0000-0001-9525-5724
Mostafa
Qorbani
mqorbani1379@yahoo.com
6
Department of Community Medicine, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.
AUTHOR
https://orcid.org/0000-0001-9465-7588
Mahsa
Mohammad Amoli
amolimm@tums.ac.ir
7
Metabolic Disorders Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
https://orcid.org/0000-0002-9168-923
Maryam
Shahrabi-Farahani
maryam_shahrabif@yahoo.com
8
Metabolic Disorders Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
https://orcid.org/0000-0003-4998-615X
OTHERS_CITABLE
The Pathway from Gene Therapy to Genome Editing: A Nightmare or Dream
The gene therapy approach has largely been improved by the development of new methods in gene transfer and genome editing. The use of CART cells was first approved in 2018 by FDA for ex vivo treatment of B cell acute lymphoblastic leukemia and in vivo treatment of retinal dystrophy. This revolutionary trend is expected to continue as the clinical vision develops and the technical capacity improves.
http://ijmcmed.org/article-1-1042-en.pdf
2020-01-01
69
70
10.22088/IJMCM.BUMS.8.2.69
Gene Therapy
Genome Editing
Mandana
Hasanzad
mandanahasanzad@yahoo.com
1
Medical Genomics Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran; Personalized Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
https://orcid.org/0000-0002-0538-1135
Bagher
Larijani
Larijanib1340@gmail.com
2
Personalized Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
AUTHOR
https://orcid.org/0000-0001-5386-7597